16+
Major trials tracked
Antibody-drug conjugates · Live ClinicalTrials.gov data
Datopotamab deruxtecan (Datroway) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 datopotamab deruxtecan trials on ClinicalTrials.gov by enrolment, 8 of them actively recruiting. The next phase 3 primary completion among them is expected Sept 2026. Refreshed daily — add up to four competitors to compare pipelines side by side.
12
Phase 3 trials
8
Actively recruiting
Sept 2026
Next phase 3 primary completion
17,657
Participants across trials
AstraZeneca
Lead sponsor by trial count
datopotamab deruxtecan (16)16 active2010–2032
datopotamab deruxtecan
'10
'12
'14
'16
'18
'20
'22
'24
'26
'28
'30
'32
datopotamab deruxtecan
I-SPYP2
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)P3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)P3
TROPION-Lung08P3
NeoCOAST-2P2
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)P3
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)P2
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)P3
AVANZARP3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)P3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerP3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)P3
TROPION-Lung10P3
TROPION-Lung14P3
TROPION-Lung15P3
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaP2
Upcoming readouts
13 ahead · datopotamab deruxtecan
Select a trial to load its full ClinicalTrials.gov record.
Key datopotamab deruxtecan trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06417814 | TROPION-Lung15 — A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum … | Phase 3 | Recruiting | Sept 2026 |
| NCT06103864 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy i… | Phase 3 | Recruiting | Jul 2027 |
| NCT06350097 | TROPION-Lung14 — Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally… | Phase 3 | Recruiting | Mar 2028 |
| NCT06357533 | TROPION-Lung10 — Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamou… | Phase 3 | Recruiting | Dec 2029 |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Wit… | Phase 3 | Active, not recruiting | May 2024 |
| NCT05104866 | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Part… | Phase 3 | Active, not recruiting | Jul 2024 |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or… | Phase 3 | Active, not recruiting | Aug 2025 |
| NCT05629585 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage … | Phase 3 | Active, not recruiting | Sept 2027 |
| NCT05687266 | AVANZAR — Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advance… | Phase 3 | Active, not recruiting | Nov 2027 |
| NCT06112379 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-… | Phase 3 | Active, not recruiting | Nov 2028 |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell… | Phase 3 | Active, not recruiting | May 2029 |
| NCT05215340 | TROPION-Lung08 — Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advan… | Phase 3 | Active, not recruiting | Mar 2030 |
Related drug pipelines
FAQ
- How many clinical trials are running for datopotamab deruxtecan?
- ClinicalTrials.gov lists more than 16 phase 2–4 datopotamab deruxtecan trials. This page tracks the 16 largest by enrolment: 4 phase 2, 12 phase 3, and 0 phase 4 among them, with 8 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare datopotamab deruxtecan against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.